NGF — NGF (nerve growth factor, ligand)

NGF (NGF (nerve growth factor, ligand)) is a lever-L3 non-opioid analgesic target. Its promoter reads γ = 1.4688, placing it on the firing-threshold scale at |h_sp| = 0.68516; the intervention direction is to block the NGF->TrkA sensitising drive. The read is reproducible [V]; the clinical magnitude is open [O].

NGF is read from its human promoter by the same deterministic engine used across the map (nearest-neighbour stacking energy → γ = 1.4688; R19 scale → |h_sp| = 0.68516). The read places the gene in lever L3; its selectivity is cited Layer-2 biology, and every clinical magnitude (potency, dose, efficacy, safety) is graded [O].

The read

NGF — NGF (nerve growth factor, ligand) sits in the threshold map at γ = 1.4688, |h_sp| = 0.68516 (barrier 0.539343). It belongs to lever L3; the intervention direction is to block the NGF->TrkA sensitising drive (anti-NGF).

selectivity (cited) peripheral sensitiser; anti-NGF efficacy in OA/LBP (rapidly-progressive-OA caveat)

burden Tier-1 musculoskeletal (#1 disability burden)

Grades

• read [V] reproducible promoter-switch-threshold read
• order [F] forced by reads
• lever [O] cited biology: gamma places the gene in the lever map; the receptor/network mechanism is NOT derived
• mechanism [O] cited biology: gamma places the gene in the lever map; the receptor/network mechanism is NOT derived
• clinical magnitude [O] OPEN — not a voltage, potency, dose, selectivity-in-vivo, or effect

Firewall. γ here is a read of promoter switch-threshold structure only — never this channel's activation voltage, a candidate's potency, a dosing quantity, an in-vivo selectivity, or a clinical effect. Those magnitudes are [O] open.

Source

Lane 2010 NEJM 363:1521 (tanezumab OA); anti-NGF Phase-III programme · reproduce the read (engine)

See also: its lever · prioritisation · grading.